Sera Prognostics, INC 10-Q quarterly reports

Sera Prognostics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses, increased operating expenses, and strategic workforce reductions alongside positive clinical study results and expanded partnerships.

Sera Prognostics reports a strengthened cash position and strategic commercial expansion, supported by positive clinical trial results for its PreTRM test, despite ongoing net losses.

Sera Prognostics, a women's health company, reported a reduced net loss in Q2 2025, bolstered by a recent $53.6M capital raise and positive clinical trial data for its PreTRM test.

Sera Prognostics announces its Q1 2025 financial results, focusing on commercializing the PreTRM test and advancing its pipeline.

Sera Prognostics reports a net loss of $7.9 million for the third quarter of 2024, while strategically focusing on commercializing its PreTRM test and reducing operating expenses.

Sera Prognostics reported a net loss of $16.4 million for the first half of 2024, while focusing on commercializing its PreTRM test and advancing its product pipeline.

Sera Prognostics reports a net loss of $8.1 million for the first quarter of 2024, while highlighting advancements in their PreTRM test and pipeline development.